Development targeted for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The agreement also grants Glaukos exclusive rights to RevOpsis’ proprietary RevMod™ platform in geographic atrophy, DME, DR, RVO, and nAMD for the discovery and development of up to four additional next-generation retinal biologic candidates.

Engineered as a first-in-class tri-specific biologic in a high concentration formulation, RO-104 is designed to simultaneously block VEGF-A and VEGF-C while also potently inhibiting Ang-2, three clinically validated angiogenic pathways implicated in the progression of vascular diseases. RO-104 has demonstrated superior preclinical efficacy in established animal models when compared to approved anti-VEGF therapeutics.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.